Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 13, 2022 (4 years ago)

Aprepitant Capsule

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

cGMP deviations: Temperature abuse

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

Aprepitant Capsule, USP, 40 mg, 1 capsule per unit dose package, Rx only, MFG: Sandoz Pharma, NDC 0781-2321-06

Affected NDC 0781-2321-06

Compare with the code on your package — it is the most precise check available.

Drug: Aprepitant

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Aprepitant
NDC 00781-2321
40 mg/1 Capsule
Oral
Sandoz Inc Rx
Recalling firm
Mckesson Medical-Surgical Inc. Corporate Office
NDC code
0781-2321-06
Origin
VA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1027-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Aprepitant recalls

See all
Class II · Moderate risk

Merck Emend

Presence of particulate matter: potential presence of metal particulates in the product.

Ongoing Particulate / foreign matter Merck Sharp & Dohme LLC NDC 0006-3066-03 D-0241-2026
Class III · Low risk

Aprepitant Capsules

Shortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack.

Terminated Failed specification Glenmark Pharmaceuticals Inc., USA NDC 68462-583-40 D-0349-2019
Class II · Moderate risk

Aprepitant active pharmaceutical ingredient packaged in varying…

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Terminated Cross-contamination Attix Pharmaceuticals D-523-2015

Other recalls by Mckesson Medical-Surgical Inc. Corporate Office

All 2022 recalls
Class II · Moderate risk

Infuvite Adult

Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 54643-5649-1 D-0401-2025
Class II · Moderate risk

Medroxyprogesterone Acetate Injectable Suspension

Severe thunderstorms caused transit delays of certain cold chain products that were shipped on 02-Apr-2025 and delivered after the 48-hours specified delivery time, on 07-Apr-2025 and 08-Apr-2025. The affected products may not have been stored at the recommended labeled storage conditions which may have impacted the safety, quality, identity, potency and purity of the product.

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 55150-0330-01 D-0400-2025
Class II · Moderate risk

BENLYSTA (belimumab)

CGMP Deviations; potential temperature excursions due to transit delays

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 49401-102-01 D-0540-2025
Class II · Moderate risk

Evenity

CGMP Deviations; potential temperature excursions due to transit delays

Ongoing Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 55513-880-02 D-0539-2025